Emcure halves price of its semaglutide weight loss drug Poviztra after Novo Nordisk patent expiry — check new rates

Patent expirations are a critical event in the pharma sector, often leading to generic competition and significant price drops. This move by Emcure will reshape the market for weight management drugs in India.

Neutral for Emcure (volume vs. margin); negative for other players with higher-priced semaglutide offerings.

For Indian markets, this story mainly matters for the pharma pocket. The current signal is mixed, so traders should watch whether the effect spreads across the sector or stays limited to a single name.

Watch whether the next market session confirms the setup described here: Increased market share and accessibility vs. potential margin pressure due to significant price reduction. Also track volume confirmation, sector participation, and whether the move holds beyond the first reaction.

• •Emcure Pharmaceuticals reduced the price of its weight management drug Poviztra to ₹3,999 per month.
• •Effective 3 April 2026.
• •Move follows increased competition after semaglutide's patent expiration in India.
• •Risk flag: Intense price competition
• •Risk flag: Potential for reduced profitability across the segment